PRIMARY SCLEROSING CHOLANGITIS IN AN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-NEGATIVE WOMAN: DIAGNOSTIC CHALLENGES IN A POSSIBLE ATYPICAL PHENOTYPE

Authors

  • Lília Maria Machado Bersi Author
  • Giovana Reina Paini Author
  • Marina Paduan Remelli Author
  • Isabela Queiroz Guedes Author
  • Uilliane P. de Oliveira Author

DOI:

https://doi.org/10.56238/levv17n60-049

Keywords:

Primary Sclerosing Cholangitis, Cholestasis, Autoantibodies, Endoscopic Retrograde Cholangiopancreatography, Acute Cholangitis, Acute Pancreatitis

Abstract

Primary sclerosing cholangitis is a rare chronic cholestatic liver disease characterized by inflammation, fibrosis, and multifocal stricturing of the intrahepatic and/or extrahepatic bile ducts. Although its diagnosis is usually supported by cholangiographic abnormalities and may be associated with immune-mediated conditions, atypical presentations without suggestive serological markers can delay clinical recognition. This report describes a 53-year-old woman with an uncommon presentation of primary sclerosing cholangitis, initially characterized by fever, severe abdominal pain, jaundice, acute pancreatitis with peripancreatic necrosis, persistent cholestasis, and recurrent episodes of severe acute cholangitis. The diagnostic investigation was challenging because autoimmune markers were negative, immunoglobulin G4 levels were normal, and magnetic resonance cholangiopancreatography showed only mild intrahepatic bile duct dilation without typical findings of primary sclerosing cholangitis. Definitive diagnosis was established only after endoscopic retrograde cholangiopancreatography, which demonstrated multifocal biliary strictures and irregularities compatible with the disease. The patient subsequently developed Tokyo grade III acute cholangitis, requiring intensive care, vasopressor support, broad-spectrum antibiotic therapy, and referral for liver transplantation assessment. This case highlights that primary sclerosing cholangitis may present with severe systemic manifestations, pancreatitis, negative autoimmune markers, and initially inconclusive noninvasive imaging. Persistent cholestasis of unclear etiology should maintain primary sclerosing cholangitis within the differential diagnosis, even in the absence of classical clinical, serological, or radiological findings. In selected cases, endoscopic retrograde cholangiopancreatography remains essential for diagnostic clarification and timely referral to specialized hepatology care.

Downloads

Download data is not yet available.

References

1 Barberio, B., et al. (2021). Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease: A systematic review and meta-analysis. Gastroenterology.

2 Berntsen, N. L., et al. (2019). The epidemiology and risk factors of primary sclerosing cholangitis. Seminars in Liver Disease.

3 Boberg, K. M., et al. (2015). PSC – Natural history and prognostic models. Digestive Diseases.

4 Bowlus, C. L., et al. (2023). ACG clinical guideline: Primary sclerosing cholangitis. American Journal of Gastroenterology.

5 Chapman, R., et al. (2010). Guidelines for PSC management. Hepatology.

6 Chapman, M. H., et al. (2019). British Society of Gastroenterology guidelines. Gut.

7 Charatcharoenwitthaya, P., et al. (2008). Utility of serum tumor markers… Hepatology.

8 Couto, C. A., et al. (2019). Update of Brazilian Society recommendations… Arquivos de Gastroenterologia.

9 Eaton, J. E., et al. (2018). Epidemiology and natural history of PSC. Clinical Liver Disease.

10 Gidwaney, N. G., Pawa, S., & Das, K. M. (2017). Pathogenesis and clinical spectrum… World Journal of Gastroenterology.

11 Gochanour, E., Jayasekera, C., & Kowdley, K. (2020). PSC: Epidemiology and management. Clinical Liver Disease.

12 Hirschfeld, G. M., et al. (2011). UDCA in PSC. Digestive Diseases.

13 Kaplan, M. (1991). Medical approaches to PSC. Seminars in Liver Disease.

14 Karlsen, T. H., et al. (2017). PSC – a comprehensive review. Journal of Hepatology.

15 Lazaridis, K. N., et al. (2015). Role of liver biopsy in PSC. Hepatology.

16 Lee, Y. M., & Kaplan, M. M. (1995). PSC. New England Journal of Medicine.

17 Lindor, K. D., et al. (2009). Primary sclerosing cholangitis. The Lancet.

18 Loftus, E. V. Jr., et al. (2001). Colorectal neoplasia in PSC. Gastroenterology.

19 Macfaul, G. R., & Chapman, R. W. (2004). Sclerosing cholangitis. Current Opinion in Gastroenterology.

20 Mintziras, I., et al. (2016). MRI vs ERCP in PSC diagnosis. European Radiology.

21 Nicoletti, A., Maurice, J. B., & Thorburn, D. (2020). Guideline review PSC. Frontline Gastroenterology.

22 Parlak, E., et al. (2007). Endoscopic findings in PSC. Gastrointestinal Endoscopy.

23 Razumilava, N., et al. (2011). Cholangiocarcinoma risk in PSC. Hepatology.

24 Tabibian, J. H., & Bowlus, C. L. (2017). PSC: review and update. Liver Research.

25 Trivedi, P. J., et al. (2017). Overlap disease. American Journal of Gastroenterology.

26 Venkatesh, S. K., et al. (2021). MRI standards in PSC. European Radiology.

Downloads

Published

2026-05-22

How to Cite

BERSI, Lília Maria Machado; PAINI, Giovana Reina; REMELLI, Marina Paduan; GUEDES, Isabela Queiroz; DE OLIVEIRA, Uilliane P. PRIMARY SCLEROSING CHOLANGITIS IN AN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-NEGATIVE WOMAN: DIAGNOSTIC CHALLENGES IN A POSSIBLE ATYPICAL PHENOTYPE. LUMEN ET VIRTUS, [S. l.], v. 17, n. 60, p. e13202, 2026. DOI: 10.56238/levv17n60-049. Disponível em: https://periodicos.newsciencepubl.com/LEV/article/view/13202. Acesso em: 23 may. 2026.